ABSTRACT
AIMS: To study all-cause mortality in patients hospitalized with COVID-19 with or without chronic heart failure (CHF) during hospitalization and at 3 and 6 months of follow-up. METHODS AND RESULTS: The international registry Analysis of Comorbid Disease Dynamics in Patients with SARS-CoV-2 Infection (ACTIV) was conducted at 26 centres in seven countries: Armenia, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russian Federation, and Uzbekistan. The primary endpoints were in-hospital all-cause mortality and all-cause mortality at 3 and 6 months of follow-up. Of the 5616 patients hospitalized with COVID-19, 917 (16.3%) had CHF. Total in-hospital mortality was 7.6%. In-hospital mortality was higher in patients with CHF than in patients without a history of CHF [17.7% vs. 4.0%, P < 0.001; odds ratio (OR) 4.614, 95% confidence interval (CI) 3.633-5.859; P < 0.001]. The risk of in-hospital all-cause mortality correlated significantly with the severity of CHF; specifically, the risk of in-hospital all-cause mortality was greater for patients in New York Heart Association functional classes III and IV (OR 6.124, 95% CI 4.538-8.266; P < 0.001 vs. patients without CHF) than for patients in functional classes I and II (OR 2.446, 95% CI 1.831-3.267, P < 0.001 vs. patients without CHF). The risk of mortality in patients with ischemic CHF was 58% higher than in patients with non-ischaemic CHF [OR 1.58 (95% CI 1.05-2.45), P = 0.030]. In the first 3 months of follow-up, the all-cause mortality rate in patients with CHF was 10.32%, compared with 1.83% in patients without CHF (P < 0.001). At 6 months of follow-up, NYHA classes II-IV was a strong risk factor for all-cause mortality [OR 5.343 (95% CI 2.717-10.508); P < 0.001]. CONCLUSIONS: Hospitalized COVID-19 patients with CHF have an increased risk of in-hospital all-cause mortality, which remains high 6 months after discharge.
Subject(s)
COVID-19 , Heart Failure , Humans , COVID-19/complications , SARS-CoV-2 , Heart Failure/complications , Hospitalization , RegistriesABSTRACT
ЦелÑ: ÐзÑÑение оÑобенноÑÑей клиниÑеÑкого ÑеÑÐµÐ½Ð¸Ñ Ð½Ð¾Ð²Ð¾Ð¹ коÑонавиÑÑÑной инÑекÑии и влиÑÐ½Ð¸Ñ ÑопÑÑÑÑвÑÑÑÐ¸Ñ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ð¹ на иÑÑ Ð¾Ð´ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ñ Ñ Ð³Ð¾ÑпиÑализиÑованнÑÑ Ð±Ð¾Ð»ÑнÑÑ Ñ Ð¸Ð½ÑекÑией SARS-CoV-2 в пеÑвÑÑ Ð¸ вÑоÑÑÑ Ð²Ð¾Ð»Ð½Ñ Ð¿Ð°Ð½Ð´ÐµÐ¼Ð¸Ð¸.ÐеÑÐ¾Ð´Ñ Ð¸ ÑезÑлÑÑаÑÑ. ÐÐ»Ñ Ð¾Ñенки оÑобенноÑÑей ÑеÑÐµÐ½Ð¸Ñ COVID-19 в ÐвÑазийÑком Ñегионе бÑли ÑÐ¾Ð·Ð´Ð°Ð½Ñ Ð¼ÐµÐ¶Ð´ÑнаÑоднÑе ÑегиÑÑÑÑ ÐÐТÐÐ 1 и во вÑÐµÐ¼Ñ Ð²ÑоÑой Ð²Ð¾Ð»Ð½Ñ Ð¿Ð°Ð½Ð´ÐµÐ¼Ð¸Ð¸ ÐÐТÐÐ 2. ÐÐ°Ð±Ð¾Ñ Ð±Ð¾Ð»ÑнÑÑ Ð² ÑегиÑÑÑ ÐÐТÐÐ 1 пÑоводили Ñ 29.06.20 по 29.10.20, набÑано 5 397 паÑиенÑов. ÐÑием паÑиенÑов на ÑÑÐµÑ Ð² ÐÐТÐÐ 2 пÑоводили Ñ 01.11.20 до 30.03.21, набÑано 2 665 болÑнÑÑ .РезÑлÑÑаÑÑ. ÐоÑпиÑалÑÐ½Ð°Ñ Ð»ÐµÑалÑноÑÑÑ ÑнизилаÑÑ Ð² пеÑиод вÑоÑой Ð²Ð¾Ð»Ð½Ñ Ð¿Ð°Ð½Ð´ÐµÐ¼Ð¸Ð¸ и ÑоÑÑавила 4,8 % пÑоÑив 7,6 % в пеÑиод пеÑвой волнÑ. РпеÑиод вÑоÑой Ð²Ð¾Ð»Ð½Ñ Ð¿Ð°ÑиенÑÑ Ð±Ñли ÑÑаÑÑе, имели болÑÑе ÑопÑÑÑÑвÑÑÑÐ¸Ñ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ð¹ и поÑÑÑпали в ÑÑаÑÐ¸Ð¾Ð½Ð°Ñ Ð² более ÑÑжелом ÑоÑÑоÑнии, паÑиенÑÑ Ð¸Ð¼ÐµÐ»Ð¸ более вÑÑокий ÑÑÐ¾Ð²ÐµÐ½Ñ Ð¿Ð¾Ð»Ð¸Ð¼Ð¾ÑбидноÑÑи. РпеÑиод вÑоÑой Ð²Ð¾Ð»Ð½Ñ Ð¿Ð°Ð½Ð´ÐµÐ¼Ð¸Ð¸ ÑвелиÑилаÑÑ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°ÐµÐ¼Ð¾ÑÑÑ Ð±Ð°ÐºÑеÑиалÑной пневмонией и ÑепÑиÑом, но Ñеже вÑÑÑеÑалиÑÑ ÑÑÐ¾Ð¼Ð±Ð¾Ð·Ñ Ð³Ð»ÑÐ±Ð¾ÐºÐ¸Ñ Ð²ÐµÐ½ и «ÑиÑокиновÑй ÑÑоÑм¼. Ðаиболее неблагопÑиÑÑнÑми Ð´Ð»Ñ Ð¿Ñогноза ÑмеÑÑноÑÑи, как в пеÑвÑÑ, Ñак и во вÑоÑÑÑ Ð²Ð¾Ð»Ð½Ñ Ñпидемии бÑли ÑоÑеÑÐ°Ð½Ð¸Ñ ÑопÑÑÑÑвÑÑÑÐ¸Ñ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ð¹: аÑÑеÑиалÑÐ½Ð°Ñ Ð³Ð¸Ð¿ÐµÑÑÐµÐ½Ð·Ð¸Ñ (ÐÐ) + Ñ ÑониÑеÑÐºÐ°Ñ ÑеÑдеÑÐ½Ð°Ñ Ð½ÐµÐ´Ð¾ÑÑаÑоÑноÑÑÑ (ХСÐ) + ÑÐ°Ñ Ð°ÑнÑй Ð´Ð¸Ð°Ð±ÐµÑ (СÐ) + ожиÑение, ÐÐ + иÑемиÑеÑÐºÐ°Ñ Ð±Ð¾Ð»ÐµÐ·Ð½Ñ ÑеÑдÑа (ÐÐС) + ХСР+ СÐ, ÐÐ + ÐÐС + ХСР+ ожиÑение.ÐаклÑÑение. У паÑиенÑов во вÑоÑÑÑ Ð²Ð¾Ð»Ð½Ñ Ð¿Ð°Ð½Ð´ÐµÐ¼Ð¸Ð¸ наблÑдалоÑÑ Ð±Ð¾Ð»ÐµÐµ обÑиÑное поÑажение Ñкани Ð»ÐµÐ³ÐºÐ¸Ñ , ÑаÑе возникала ÑебÑилÑÐ½Ð°Ñ Ð»Ð¸Ñ Ð¾Ñадка, бÑли вÑÑе ÑÑовни С-ÑеакÑивного белка и ÑÑопонина, ниже ÑÑовни гемоглобина и лимÑоÑиÑов. ÐÑо, веÑоÑÑно, ÑвÑзано Ñ ÑазлиÑной ÑакÑикой гоÑпиÑализаÑии паÑиенÑов в пеÑвÑÑ Ð¸ вÑоÑÑÑ Ð²Ð¾Ð»Ð½Ñ Ð¿Ð°Ð½Ð´ÐµÐ¼Ð¸Ð¸ в ÑÑÑÐ°Ð½Ð°Ñ , пÑинÑвÑÐ¸Ñ ÑÑаÑÑие в ÑоÑмиÑовании ÑегиÑÑÑов ÐÐТÐÐ 1 и ÐÐТÐÐ 2.
Subject(s)
COVID-19 , Irritable Bowel Syndrome , Humans , Pandemics , SARS-CoV-2ABSTRACT
Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardiovascular and non-cardiovascular morbidity and mortality. Regardless of therapeutic attempts in COVID-19, vaccination remains the most promising global approach at present for controlling this disease. There are several concerns and misconceptions regarding the clinical indications, optimal mode of delivery, safety and efficacy of COVID-19 vaccines for patients with HF. This document provides guidance to all healthcare professionals regarding the implementation of a COVID-19 vaccination scheme in patients with HF. COVID-19 vaccination is indicated in all patients with HF, including those who are immunocompromised (e.g. after heart transplantation receiving immunosuppressive therapy) and with frailty syndrome. It is preferable to vaccinate against COVID-19 patients with HF in an optimal clinical state, which would include clinical stability, adequate hydration and nutrition, optimized treatment of HF and other comorbidities (including iron deficiency), but corrective measures should not be allowed to delay vaccination. Patients with HF who have been vaccinated against COVID-19 need to continue precautionary measures, including the use of facemasks, hand hygiene and social distancing. Knowledge on strategies preventing SARS-CoV-2 infection (including the COVID-19 vaccination) should be included in the comprehensive educational programmes delivered to patients with HF.